NYSENYSEARCA:ASXC

Asensus Surgical Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive ASXC News and Ratings via Email

Sign-up to receive the latest news and ratings for Asensus Surgical and its competitors with MarketBeat's FREE daily newsletter.


About Asensus Surgical

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera; and SurgiBot System, a single-port robotically enhanced laparoscopic surgical platform. Its products also comprise instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is based in Durham, North Carolina.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Asensus Surgical (NYSENYSEARCA:ASXC) Frequently Asked Questions

What stocks does MarketBeat like better than Asensus Surgical?

Wall Street analysts have given Asensus Surgical a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Asensus Surgical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Asensus Surgical's key executives?

Asensus Surgical's management team includes the following people:
  • Mr. Anthony Fernando, Pres, CEO & Director (Age 49, Pay $1.41M)
  • Mr. Shameze Rampertab B.Sc. MBA, CA, CPA, Exec. VP & CFO (Age 54, Pay $179.55k)
  • Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 48)
  • Mr. Paul Ziegler, VP of Sales
  • Ms. Amanda Owens, Global Head of People
  • Dr. Stephanie M. Fitts, VP of Clinical, Quality and Regulatory Affairs (Age 55)

Who are some of Asensus Surgical's key competitors?

What is Asensus Surgical's stock symbol?

Asensus Surgical trades on the New York Stock Exchange (NYSE)New York Stock Exchange (NYSE)ARCA under the ticker symbol "ASXC."

How do I buy shares of Asensus Surgical?

Shares of ASXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How many employees does Asensus Surgical have?

Asensus Surgical employs 133 workers across the globe.

What is Asensus Surgical's official website?

The official website for Asensus Surgical is www.asensus.com.

Where are Asensus Surgical's headquarters?

Asensus Surgical is headquartered at 1 Tw Alexander Drive, Durham, North Carolina 27703.

How can I contact Asensus Surgical?

Asensus Surgical's mailing address is 1 Tw Alexander Drive, Durham, North Carolina 27703. The company can be reached via phone at 919 765 8400.


This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.